Recent abolon transactions

Afinum acquires a majority stake in evitria

Abolon was mandated by Afinum, the DACH-based private equity firm, on its acquisition of a majority stake in Swiss biotech company evitria, which provides custom antibodies for research purposes. evitria has been conducting more than 30,000 transfections and has been producing more than 5,000 different antibodies to date. The company’s success is based on a unique, highly standardized and automatized production process that minimizes throughput times and guarantees high concentrations and quality levels, thereby perfectly addressing its customers’ need for specific, tailor-made antibodies. Its business model has allowed evitria to build a reputation of a superior biotech specialist and trustworthy outsourcing partner. The transaction has been closed today. The enterprise value was not made publicly available. Abolon was exclusively mandated by Afinum.

Read more

Healthcare insights

How will new landmark legislation affect Germany’s private hospital groups

The new Hospital Structure Act could force small, low quality public sector hospitals to the wall. But it could also cap growth for big private operators. We examine likely scenarios.

Read more

Healthcare deal of the month

December 2015: Etac acquires Convaid

The Deal: In December 2015, Etac, a Sweden-based developer and manufacturer of mobility solutions and rehab products, acquired Convaid Products

Read more


Abolon is a strategy consulting and corporate finance company with an exclusive focus on the healthcare sector.

We pride ourselves on our specialist insights into the various segments of the healthcare markets in Europe and beyond.

Our global network in the healthcare sector provides us with unmatched dealflow of large and mid-sized healthcare opportunities.

Facts & figures

  • Healthcare forms an enormous ...
  • Stable healthcare sector attracts ...
  • The global pharmaceutical market ...
  • The healthcare sector offers ...
  • Abolon has advised on ...
  • Healthcare forms an enormous part of developed country's economy, contributing over 10 percent of gross domestic product (GDP).
  • Stable healthcare sector attracts record private equity investments.
  • The global pharmaceutical market is expected to grow from 995 $bn in 2011 to 1160 $bn in 2016
  • The healthcare sector offers numerous opportunities at low risk
  • Abolon has advised on 4 successful healthcare transactions in the last 18 months.